Clinical trials: Leukocytes
Eosinophilic Esophagitis
Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis
This study is being done to see if allergy patch testing (APT) can help predict effective dietary therapy in patients with eosinophilic esophagitis.
- Trial name
- EoE (NCT02227836)
- Testing
- Allergy Patch Testing
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Eosinophilic Esophagitis
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants…
- Trial name
- NCT04753697
- Testing
- CC-93538
- Where
- 212 sites in United States, Argentina and 13 more
- Volunteers
- 430 people
- Sponsor
- Celgene
Neutropenia
Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)
This study aims to evaluate the pharmacokinetics of posaconazole (POS) administered intravenously (IV) or orally to immunocompromised pediatric participants.
- Trial name
- NCT02452034
- Testing
- Posaconazole IV solution, Posaconazole powder for oral suspension
- Volunteers
- 118 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophagitis
A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
Eosinophilic esophagitis (EE) is an increasingly recognized condition characterized by dysphagia, food impaction or other obstructive esophageal symptoms in children and young adults.
- Trial name
- NCT00123630
- Testing
- omalizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Postoperative Recovery
A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty
This study will evaluate the safety, tolerability and effect of GRF6021 on clinical recovery parameters in participants undergoing primary hip or knee arthroplasty.
- Trial name
- NCT03981419
- Testing
- GRF6021
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Alkahest, Inc.
Bone Marrow Failure Syndrome, Thalassemia
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum…
- Conditions
- Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia
- Trial name
- NCT03513328
- Testing
- Thiotepa--single daily dose, Thiotepa--escalated dose
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Immunologic Deficiency Syndromes
Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans
The purpose of this study is to test wether orally administered Beta-glucan has systemic effects in humans.
- Trial name
- BG (NCT01727895)
- Testing
- Beta-glucan (Glucan #300®)
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Neutropenia, Breast Cancer
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
A Phase I, dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of F-627 in female breast cancer patients who received up to 4 cycles of Epirubicin and Cyclophosphamide.
- Trial name
- NCT02527746
- Testing
- F-627, EC regimen
- Volunteers
- 18 people
- Sponsor
- EVIVE Biotechnology
Cytomegalovirus Disease, Cytomegalovirus Infections
Letermovir Use in Heart Transplant Recipients
This is an open label trial in which letermovir will be given as prophylaxis for the prevention of cytomegalovirus (CMV) infection and disease to all heart transplants who are at risk for cytomegalovirus.
- Conditions
- Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity
- Trial name
- NCT04904614
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Tufts Medical Center
ALL, B Cell Lymphoma
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
Background: Although progress has been made in treating children with B-cell cancers such as leukemia or lymphoma, many children do not respond to the standard treatments.
- Conditions
- ALL, B Cell Lymphoma, Leukemia, Large Cell Lymphoma
- Trial name
- NCT01593696
- Testing
- Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Colon Cancer
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever
- Trial name
- NCT00911170
- Testing
- Pegfilgrastim, Bevacizumab, Standard Chemotherapy
- Where
- 154 sites in United States, Australia and 15 more
- Volunteers
- 847 people
- Sponsor
- Amgen
Alveolar Ridge Preservation, Tooth Extraction
A 14 Weeks Longitudinal Study to Investigate the Effect of Leukocyte- Platelet Rich Fibrin Plug on the Quality of the Newly Formed Bone in Ridge Preservation Procedure Following a Tooth Extraction. It is a Clinical, Radiographic and Histomorphometric Study.
This 14 weeks longitudinal study will be conducted from March 2018 to June 2020, with a 40 participants. No subjects has received placebo medication at any point in the research procedures.
- Trial name
- NCT03487718
- Testing
- Leukocyte platelet rich fibrin plug + d-PTFE membrane, d-PTFE membrane
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Firas Al Yafi
Lymphoma
Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT
Evaluate the safety of natural killer (NK) cell infusion using CD56 monoclonal antibody selected with Miltenyi Biotec system following nonmyeloablative stem cell transplantation (SCT) from mismatched donors.
- Trial name
- NCT00586703
- Testing
- NK-CD56
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- David Rizzieri, MD
Myelogenous Leukemia
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
In this study, the efficacy and safety of nilotinib 400 mg twice daily, will be compared with imatinib 400 mg twice daily in patients with a suboptimal response to imatinib for their Philadelphia chromosome-positive (Ph+) Chronic…
- Trial name
- ENEST (NCT00519090)
- Testing
- Imatinib, Nilotinib (AMN107)
- Where
- 80 sites in United States, Australia and 8 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Eosinophilic Gastritis, Eosinophilic Duodenitis
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002), given monthly for 6 doses, in patients with moderately to severely active Eosinophilic…
- Trial name
- ENIGMA 2 (NCT04322604)
- Testing
- lirentelimab (AK002)
- Where
- 60 sites in United States
- Volunteers
- 181 people
- Sponsor
- Allakos Inc.
Eosinophilic Esophagitis
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic…
- Trial name
- KRYPTOS (NCT04322708)
- Testing
- lirentelimab (AK002)
- Where
- 78 sites in United States, Australia and 1 more
- Volunteers
- 277 people
- Sponsor
- Allakos Inc.
Aplastic Anemia
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
Severe aplastic anemia, characterized by pancytopenia and a hypocellular bone marrow, is effectively treated by immunosuppressive therapy, usually a combination of antithymocyte globulin (ATG) and cyclosporine (CsA).
- Trial name
- NCT00065260
- Testing
- Campath-1H, r-ATG, CsA
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446459
- Testing
- mycophenolate mofetil (CellCept)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
Metastatic Melanoma, Skin Cancer
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Background: Some cancer treatments collect a patient s own blood cells to use as specialized cancer-fighting cells. Collected white blood cells known as PBL (peripheral blood lymphocytes) can use to isolate special cells that can…
- Trial name
- NCT01495572
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Churg-Strauss Syndrome, Eosinophilic Asthma
Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
In this project the investigators will look for auto-antibodies to relevant proteins both in native form and importantly in post-translationally modified forms.
- Conditions
- Churg-Strauss Syndrome, Eosinophilic Asthma, Eosinophilic Esophagitis, Eosinophilic Pneumonia
- Trial name
- IDEA (NCT04671446)
- Testing
- Autoantibody ELISA, Granulocyte Immunofluorescence
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London